An interventional study of CM310 in IgG4 Related Disease, sponsored by Beijing Friendship Hospital. Completed at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.
Sponsored by Beijing Friendship Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 41 studies in Immunoglobulin G4-Related Disease with a site in China — 24 open to participants now, 28 under way, 5 of them phase 3. Immunoglobulin G4-Related Disease · China.
Among the 41 studies in Immunoglobulin G4-Related Disease with a site in China, this one is the 29th largest by enrollment of the 37 interventional ones that give a count, is one of 6 that started in 2023, is one of 11 with no phase, and was the 15th registered.
73 studies on the registry are indexed under Immunoglobulin G4-Related Disease; 40 are open to participants now.
Browse Immunoglobulin G4-Related Disease studies →24 of the 41 studies in Immunoglobulin G4-Related Disease with a site in China are open now. Recruiting first, the newest first:
Amgen · Sites in China, United States, Brazil and 5 more countries
Ages 2–18
Sanofi · Sites in China, United States, Argentina and 16 more countries
Ages 18+
Chinese PLA General Hospital · Sites in China
Ages 18–75
Peking Union Medical College Hospital · Sites in China
Ages 18–75
China Immunotech (Beijing) Biotechnology Co., Ltd. · Sites in China
Ages 18–65
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 27 Immunoglobulin G4-Related Disease studies recruiting now, 11 (41%) set no upper age limit and 13 (48%) stop at 75 or younger; 3 take children under 18; 3 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
41 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 8 · Phase 3 6 · Phase 4 3
First in 2012; this study’s year is marked. 6 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 20 is below the median of 48 across 52 interventional studies indexed under Immunoglobulin G4-Related Disease.
Median enrollment 58 across the 37 interventional studies, 780 across the 4 observational. Of the 3 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 41 have an industry lead sponsor. The 10 most frequent:
Beijing Friendship Hospital is the lead sponsor of 217 studies on the registry; 94 are open to participants now.
Beijing Friendship Hospital has 1 study filed under Immunoglobulin G4-Related Disease — fewer than ten, so there is no comparison to draw.
7 of the studies in Immunoglobulin G4-Related Disease with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03023371Peking Union Medical College HospitalNational Registry of IgG4-RD in China | 2026-12 |
| NCT06285279Nanjing University School of MedicineThe BCMA/CD19 Dual Targeted CAR-T Cell in Participants With Autoimmune Kidney Diseases | 2026-12-31 |
| NCT06978738Changzhou No.2 People's HospitalUCAR T-cell Therapy Targeting CD19/ BCMA in Patients With Relapse/ Refractory Autoimmune Diseases | 2027-05 |
| NCT06978647China Immunotech (Beijing) Biotechnology Co., Ltd.A Clinical Study of YTS109 Cell in R/R Autoimmune Diseases | 2027-05-19 |
| NCT06497387Tongji HospitalSafety and Efficacy of PRG-1801 for Refractory Lupus Nephritis and IgG4-Related Disease | 2027-07 |
Add all 7 to your calendar (.ics) → With an account.
Among the 41 studies in Immunoglobulin G4-Related Disease with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is a single-arm study initiated to evaluate the efficacy and safety of CM310 in subjects with recurrent IgG4-related disease.
This study includes three stages: screening period, treatment period and safety follow-up period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CM310, subcutaneous
Biological: CM310
CM310 Injection
Response rate
Response rate after administration for 12 weeks
Time frame: up to week 12
Change in RI and Physician Global Assessment (PGA) scores
Change in RI and Physician Global Assessment (PGA) scores from baseline
Time frame: up to week 12
Rescue therapy rate
Rescue therapy was defined as the initiation of any additional immunosuppressive or glucocorticoid treatment beyond the protocol-specified regimen due to insufficient efficacy or disease flare. The type and dose of rescue therapy will be recorded.
Time frame: From baseline to Week 12
Plan to share: No — Data are not available for sharing due to patient privacy and institutional ethical restrictions.
No publications or documents are linked to this record.
Ran from Feb 2023 to primary completion in Feb 2024, 12 months.
Completion moved once since we started tracking on Sep 25, 2026: Feb 2024 → Apr 2024, on Nov 18, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Stapokibart
Immunoglobulin G4-Related Disease →